Relmada Therapeutics, Inc. RLMD Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s additional paid-in capital?
- Relmada Therapeutics, Inc. (RLMD) reported additional paid-in capital of $935.95M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Relmada Therapeutics, Inc.'s additional paid-in capital increased by 37.5% year-over-year, from $680.85M to $935.95M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s additional paid-in capital has grown at a 22.5% compound annual growth rate (CAGR), from $284.88M to $784.71M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.